Endosense, a Swiss medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, announced that it has received US$ 36m in Series B financing.
The round was led by Edmond de Rothschild Investment Partners (EdRIP), with additional participation from Neomed, Gimv, VI Partners (VI), Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie.
The Geneve-based company will use the proceeds in order to fund the European commercialization and U.S. Premarket Approval (PMA) clinical study of the company’s proprietary force-sensing ablation catheter, the TactiCath.
FinSMEs
01/09/2009